Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Prior to the commencement of this study, it was already known that rivaroxaban is partially cleared via the kidneys and an influence of renal insufficiency on rivaroxaban pharmacokinetics and exposure was anticipated. WHAT THIS STUDY ADDS • As many patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2010-11, Vol.70 (5), p.703-712
Hauptverfasser:	Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Halabi, Atef, Maatouk, Haidar, Klause, Norbert, Lufft, Volkmar, Wand, Dominic D., Philipp, Thomas, Bruck, Heike
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Area Under Curve Biological and medical sciences Cohort Studies Creatinine - metabolism Factor Xa inhibitor Factor Xa Inhibitors Female Half-Life Humans Male Medical sciences Metabolic Clearance Rate Middle Aged Morpholines - pharmacokinetics Morpholines - pharmacology Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure oral anticoagulants Pharmacokinetics Pharmacology. Drug treatments Renal failure renal impairment Renal Insufficiency - metabolism Rivaroxaban Thiophenes - pharmacokinetics Thiophenes - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!